



Patient Information	Specimen Information	Client Information
029A1, ES DOB: 11/07/2020 AGE: 13M Gender: M Phone: NG Patient ID: 029A1	Specimen: WC233853D Requisition: 0000203 Collected: 01/04/2022 Received: 01/11/2022 / 08:48 EST Reported: 01/12/2022 / 13:47 EST	Client #: 11118385 CA000159 JOSLIN LESSARD RSCH Attn: SARAH LESSARD 1 JOSLIN PL BOSTON, MA 02215-5306

Test Name	In Range	Out Of Range	Reference Range	Lab
LIPID PANEL, STANDARD				
CHOLESTEROL, TOTAL	168		<170 mg/dL	NL1
HDL CHOLESTEROL	47		>45 mg/dL	NL1
TRIGLYCERIDES	51		<75 mg/dL	NL1
LDL-CHOLESTEROL	108		<110 mg/dL (calc)	NL1
LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164)				
CHOL/HDL-C RATIO	3.6		<5.0 (calc)	NL1
NON HDL CHOLESTEROL		121 H	<120 mg/dL (calc)	NL1
For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.				
GLUCOSE	83		65-99 mg/dL	NL1
Fasting reference interval				
C-REACTIVE PROTEIN	7.6		<8.0 mg/L	NL1
INSULIN	8.4		uIU/mL	NL1
Reference Range < or = 19.6				
Risk:				
Optimal < or = 19.6				
Moderate NA				
High >19.6				
Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on Quest Diagnostics population data from 12/2011.				

This insulin assay shows strong cross-reactivity for some insulin analogs (lispro, aspart, and glargine) and much lower cross-reactivity with others (detemir, glulisine).

PERFORMING SITE:

NL1 QUEST DIAGNOSTICS LLC, 200 FOREST STREET 3RD FLOOR,SUITE B, MARLBOROUGH, MA 01752-3023 Laboratory Director: SALIM E KABAWAT,MD, CLIA: 22D0076229

LIST OF RESULTS PRINTED IN THE OUT OF RANGE COLUMN:

NON HDL CHOLESTEROL	121 H	<120 mg/dL (calc)	NL1
For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.			